Margot Revel, Mikel Rezola Artero, Houcine Hamidi, Anne Grunenwald, Loris Blasco, Yann A. Vano, Stephane Marie Oudard, Rafael Sanchez-Salas, Petr Macek, Lara Rodriguez Sanchez, Xavier Cathelineau, Benoit Vedié, Catherine Sautes-Fridman, Wolf Herman Fridman, Lubka T. Roumenina, Marie-Agnes Dragon-Durey
{"title":"Humoral complementomics – exploration of noninvasive complement biomarkers as predictors of renal cancer progression","authors":"Margot Revel, Mikel Rezola Artero, Houcine Hamidi, Anne Grunenwald, Loris Blasco, Yann A. Vano, Stephane Marie Oudard, Rafael Sanchez-Salas, Petr Macek, Lara Rodriguez Sanchez, Xavier Cathelineau, Benoit Vedié, Catherine Sautes-Fridman, Wolf Herman Fridman, Lubka T. Roumenina, Marie-Agnes Dragon-Durey","doi":"10.1080/2162402x.2024.2328433","DOIUrl":null,"url":null,"abstract":"Despite the progress of anti-cancer treatment, the prognosis of many patients with solid tumors is still dismal. Reliable noninvasive biomarkers are needed to predict patient survival and therapy r...","PeriodicalId":19683,"journal":{"name":"Oncoimmunology","volume":"51 1","pages":""},"PeriodicalIF":7.2000,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402x.2024.2328433","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Despite the progress of anti-cancer treatment, the prognosis of many patients with solid tumors is still dismal. Reliable noninvasive biomarkers are needed to predict patient survival and therapy r...
期刊介绍：
Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy.
While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
